The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Identification and Multidimensional Optimization of an Asymmetric Bispecific IgG Antibody Mimicking the Function of Factor VIII Cofactor Activity
Open accessAbstract
In hemophilia A, routine prophylaxis with exogenous factor VIII (FVIII) requires frequent intravenous injections and can lead to the development of anti-FVIII alloantibodies (FVIII inhibitors). To overcome these drawbacks, we screened asymmetric bispecific IgG antibodies to factor IXa (FIXa) and factor X (FX), mimicking the FVIII cofactor function. Since the therapeutic potential of the lead bispecific antibody was marginal, FVIII-mimetic activity was improved by modifying its binding properties to FIXa and FX, and the pharmacokinetics was improved by engineering the charge properties of the variable region. Difficulties in manufacturing the bispecific antibody were overcome by identifying a common light chain for the anti-FIXa and anti-FX heavy chains through framework/complementarity determining region shuffling, and by pI engineering of the two heavy chains to facilitate ion exchange chromatographic purification of the bispecific antibody from the mixture of byproducts. Engineering to overcome low solubility and deamidation was also performed. The multidimensionally optimized bispecific antibody hBS910 exhibited potent FVIII-mimetic activity in human FVIII-deficient plasma, and had a half-life of 3 weeks and high subcutaneous bioavailability in cynomolgus monkeys. Importantly, the activity of hBS910 was not affected by FVIII inhibitors, while anti-hBS910 antibodies did not inhibit FVIII activity, allowing the use of hBS910 without considering the development or presence of FVIII inhibitors. Furthermore, hBS910 could be purified on a large manufacturing scale and formulated into a subcutaneously injectable liquid formulation for clinical use. These features of hBS910 enable routine prophylaxis by subcutaneous delivery at a long dosing interval without considering the development or presence of FVIII inhibitors. We expect that hBS910 (investigational drug name: ACE910) will provide significant benefit for severe hemophilia A patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia
Manco-Johnson, M. J., Abshire, T. C., Shapiro, A. D., Riske, B., Hacker, M. R., Kilcoyne, R., Ingram, J. D., Manco-Johnson, M. L., Funk, S., Jacobson, L., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067659 · Cited by 1,950 · cited 1×
“quality of life in hemophilia A patients [2].”
BackgroundCalibrated Automated Thrombin Generation Measurement in Clotting Plasma
Hemker, H. C., Giesen, P., Al Dieri, R., Regnault, V., de Smedt, E., Wagenvoord, R., Lecompte, T., & Béguin, S. (2003) · Pathophysiology of Haemostasis and Thrombosis · doi:10.1159/000071636 · Cited by 1,430
Replacing the complementarity-determining regions in a human antibody with those from a mouse
Jones, P. T., Dear, P. H., Foote, J., Neuberger, M. S., & Winter, G. (1986) · Nature · doi:10.1038/321522a0 · Cited by 1,406
Monoclonal antibodies: versatile platforms for cancer immunotherapy
Weiner, L. M., Surana, R., & Wang, S. (2010) · Nature Reviews Immunology · doi:10.1038/nri2744 · Cited by 1,283
Challenges in the development of high protein concentration formulations
Shire, S. J., Shahrokh, Z., & Liu, J. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20079 · Cited by 882
Strategies and challenges for the next generation of therapeutic antibodies
Beck, A., Wurch, T., Bailly, C., & Corvaia, N. (2010) · Nature Reviews Immunology · doi:10.1038/nri2747 · Cited by 847
Therapeutic antibodies for autoimmunity and inflammation
Chan, A. C., & Carter, P. J. (2010) · Nature Reviews Immunology · doi:10.1038/nri2761 · Cited by 837
Challenges in the Development of High Protein Concentration Formulations
Shire, S. J., Shahrokh, Z., & Liu, J. (2010) · Current Trends in Monoclonal Antibody Development and Manufacturing · doi:10.1007/978-0-387-76643-0_9 · Cited by 657
An efficient route to human bispecific IgG
Merchant, A. M., Zhu, Z., Yuan, J. Q., Goddard, A., Adams, C. W., Presta, L. G., & Carter, P. (1998) · Nature Biotechnology · doi:10.1038/nbt0798-677 · Cited by 510
Kitazawa, T., Igawa, T., Sampei, Z., Muto, A., Kojima, T., Soeda, T., Yoshihashi, K., Okuyama-Nishida, Y., Saito, H., Tsunoda, H., et al. (2012) · Nature Medicine · doi:10.1038/nm.2942 · Cited by 507
Self-citationAstermark, J., Donfield, S. M., DiMichele, D. M., Gringeri, A., Gilbert, S. A., Waters, J., Berntorp, E., & for the FENOC Study Group (2007) · Blood · doi:10.1182/blood-2006-04-017988 · Cited by 473
Dual targeting strategies with bispecific antibodies
Kontermann, R. (2012) · mAbs · doi:10.4161/mabs.4.2.19000 · Cited by 435
Mechanistic Determinants of Biotherapeutics Absorption Following SC Administration
Richter, W. F., Bhansali, S. G., & Morris, M. E. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9367-0 · Cited by 377
Berntorp, E., & Shapiro, A. D. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61139-2 · Cited by 335
Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity
Maynard, J. A., Maassen, C. B. M., Leppla, S. H., Brasky, K., Patterson, J. L., Iverson, B. L., & Georgiou, G. (2002) · Nature Biotechnology · doi:10.1038/nbt0602-597 · Cited by 287
Deng, R., Iyer, S., Theil, F.-P., Mortensen, D. L., Fielder, P. J., & Prabhu, S. (2011) · mAbs · doi:10.4161/mabs.3.1.13799 · Cited by 285 · cited 1×
“Since the half-lives of IgG antibodies are generally longer in humans than in cynomolgus monkeys [42], we expect that hBS910 would have a half-life of at least 3 weeks in humans, which is overwhelmingly longer than that of exogenous FVIII (0.”
BackgroundReduced elimination of IgG antibodies by engineering the variable region
Igawa, T., Tsunoda, H., Tachibana, T., Maeda, A., Mimoto, F., Moriyama, C., Nanami, M., Sekimori, Y., Nabuchi, Y., Aso, Y., et al. (2010) · Protein Engineering Design and Selection · doi:10.1093/protein/gzq009 · Cited by 265 · cited 2×
“Clearance of hBS106 (67 mL/day/kg) was unexpectedly larger than the clearance of human IgG4 antibody reported in mice after subcutaneous injection (3–20 mL/day/kg) [29].”
BackgroundSelf-citationLin, Y. S., Nguyen, C., Mendoza, J.-L., Escandon, E., Fei, D., Meng, Y. G., & Modi, N. B. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37962-5 · Cited by 255
Vlasak, J., Bussat, M. C., Wang, S., Wagner-Rousset, E., Schaefer, M., Klinguer-Hamour, C., Kirchmeier, M., Corvaïa, N., Ionescu, R., & Beck, A. (2009) · Analytical Biochemistry · doi:10.1016/j.ab.2009.05.043 · Cited by 252
Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges
Vugmeyster, Y. (2012) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v3.i4.73 · Cited by 242
Anti-Inhibitor Coagulant Complex Prophylaxis in Hemophilia with Inhibitors
Leissinger, C., Gringeri, A., Antmen, B., Berntorp, E., Biasoli, C., Carpenter, S., Cortesi, P., Jo, H., Kavakli, K., Lassila, R., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104435 · Cited by 221
Fay, P. J., Haidaris, P. J., & Smudzin, T. M. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)31537-0 · Cited by 213
Björkman, S., Oh, M., Spotts, G., Schroth, P., Fritsch, S., Ewenstein, B. M., Casey, K., Fischer, K., Blanchette, V. S., & Collins, P. W. (2012) · Blood · doi:10.1182/blood-2011-07-360594 · Cited by 206
Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies
Klein, C., Sustmann, C., Thomas, M., Stubenrauch, K., Croasdale, R., Schanzer, J., Brinkmann, U., Kettenberger, H., Regula, J. T., & Schaefer, W. (2012) · mAbs · doi:10.4161/mabs.21379 · Cited by 201
BiTE: Teaching antibodies to engage T-cells for cancer therapy.
Baeuerle, P. A., Kufer, P., & Bargou, R. C. (2009) · PubMed · Cited by 192
Lenting, P. J., Donath, M. J., van Mourik, J. A., & Mertens, K. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)37260-5 · Cited by 166
Practice patterns in haemophilia A therapy – global progress towards optimal care
GERAGHTY, S., DUNKLEY, T., HARRINGTON, C., LINDVALL, K., MAAHS, J., & SEK, J. (2006) · Haemophilia · doi:10.1111/j.1365-2516.2006.01189.x · Cited by 166
Engineering the variable region of therapeutic IgG antibodies
Igawa, T., Tsunoda, H., Kuramochi, T., Sampei, Z., Ishii, S., & Hattori, K. (2011) · mAbs · doi:10.4161/mabs.3.3.15234 · Cited by 143
Self-citationT cell epitope: Friend or Foe? Immunogenicity of biologics in context☆
Weber, C. A., Mehta, P. J., Ardito, M. T., Moise, L., Martin, B., & Groot, A. S. D. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.07.001 · Cited by 114
Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates
DEGROOT, A., MCMURRY, J., & MOISE, L. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.08.002 · Cited by 109 · cited 1×
“Moreover, EpiMatrix (EpiVax), another in silico immunogenicity prediction system [33,34], also predicted that the sequence of hBS910 was minimally immunogenic (supplementary Fig.”
BackgroundPepinsky, R. B., Silvian, L. F., Berkowitz, S. A., Farrington, G., Lugovskoy, A. A., Walus, L. R., Eldredge, J. K., Capili, A. D., Mi, S., Graff, C. P., et al. (2010) · Protein Science · doi:10.1002/pro.372 · Cited by 105
The A2 Subunit of Factor VIIIa Modulates the Active Site of Factor IXa
Fay, P. J., & Koshibu, K. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.30.19049 · Cited by 98
Jackman, J. K., Chen, Y., Huang, A. J. Y., Moffat, B., Scheer, J. M., Leong, S. R., Lee, W. P., Zhang, J., Sharma, N., Lu, Y., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.113910 · Cited by 91
Johnson, S., Griego, S. D., Pfarr, D. S., Doyle, M. L., Woods, R. M., Carlin, D. A., Prince, G. A., Koenig, S., Young, J. F., & Dillon, S. B. (1999) · The Journal of Infectious Diseases · doi:10.1086/314846 · Cited by 88
Immunogenicity screening in protein drug development
Walle, I. V., Gansemans, Y., Parren, P. W. H. I., Stas, P., & Lasters, I. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.3.405 · Cited by 87
Bhaskar, V., Goldfine, I. D., Bedinger, D., Lau, A., Kuan, H. F., Gross, L. M., Handa, M., Maddux, B. A., Watson, S. R., Zhu, S., et al. (2012) · Diabetes · doi:10.2337/db11-1578 · Cited by 84
Astermark, J., Donfield, S. M., DiMichele, D., Gringeri, A., Gilbert, S. A., Waters, J. A., & Berntorp, E. E. (2009) · Lund University Publications (Lund University) · Cited by 78
Mayorov, A. V., Amara, N., Chang, J. Y., Moss, J. A., Hixon, M. S., Ruiz, D. I., Meijler, M. M., Zorrilla, E. P., & Janda, K. D. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711808105 · Cited by 54
Okuda, M., & Yamamoto, Y. (2004) · Clinical and Laboratory Haematology · doi:10.1111/j.1365-2257.2004.00605.x · Cited by 47
Benincosa, L. J., Chow, F. S., Tobia, L. P., et al. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35355-8 · Cited by 44
Ragni, M. V., Fogarty, P., Josephson, N. C., Neff, A. T., Raffini, L. J., & Kessler, C. M. (2011) · Haemophilia · doi:10.1111/j.1365-2516.2011.02554.x · Cited by 43
A potent erythropoietin-mimicking human antibody interacts through a novel binding site
Liu, Z., Stoll, V. S., DeVries, P. J., Jakob, C. G., Xie, N., Simmer, R. L., Lacy, S. E., Egan, D. A., Harlan, J. E., Lesniewski, R. R., et al. (2007) · Blood · doi:10.1182/blood-2007-04-083998 · Cited by 43
Bispecific antibody: a tool for diagnosis and treatment of disease
Songsivilai, S., & Lachmann, P. J. (1990) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.1990.tb08089.x · Cited by 39
Shi, Q., Kuether, E. L., Schroeder, J. A., Fahs, S. A., & Montgomery, R. (2012) · Haemophilia · doi:10.1111/j.1365-2516.2011.02735.x · Cited by 26
Cited by
Bispecific antibodies: a mechanistic review of the pipeline
Labrijn, A. F., Janmaat, M. L., Reichert, J. M., & Parren, P. W. H. I. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0028-1 · Cited by 1,303
Emicizumab Prophylaxis in Hemophilia A with Inhibitors
Oldenburg, J., Mahlangu, J. N., Kim, B., Schmitt, C., Callaghan, M. U., Young, G., Santagostino, E., Kruse-Jarres, R., Negrier, C., Kessler, C., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1703068 · Cited by 1,121
The making of bispecific antibodies
Brinkmann, U., & Kontermann, R. E. (2017) · mAbs · doi:10.1080/19420862.2016.1268307 · Cited by 923
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors
Mahlangu, J., Oldenburg, J., Paz-Priel, I., Negrier, C., Niggli, M., Mancuso, M. E., Schmitt, C., Jiménez-Yuste, V., Kempton, C., Dhalluin, C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1803550 · Cited by 763
Next generation antibody drugs: pursuit of the 'high-hanging fruit'
Carter, P. J., & Lazar, G. A. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.227 · Cited by 754
Metadata
- Authors
- Sampei, Z., Igawa, T., Soeda, T., Okuyama-Nishida, Y., Moriyama, C., Wakabayashi, T., Tanaka, E., Muto, A., Kojima, T., Kitazawa, T., Yoshihashi, K., Harada, A., Funaki, M., Haraya, K., Tachibana, T., Suzuki, S., Esaki, K., Nabuchi, Y., & Hattori, K.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-02-28
- Volume
- 8
- Issue
- 2
- Pages
- e57479
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2011766387
- Cited by
- 336
- References
- 44
- FWCI
- 7.25
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.